Randox Logo

Meeting the testing needs for COVID-19

Multimodal Approach to SARS-CoV-2 Stratification

Solutions for both Laboratory & Individuals


In response to the COVID-19 global pandemic, Randox Laboratories have developed a range of diagnostic solutions to diagnose active SARS-CoV-2 infections, identify past infections and allow healthcare professional to monitor and support better management of COVID-19 adverse outcomes.

Randox aims to provide global testing solutions to mitigate current, resurgent societal reinfection and allow for the identification of emergent potentially more contagious variants.

Diagnosing active infections and managing resolved infections require different technologies to monitor and manage an individuals exposure to SARS-CoV-2 before and after symptom onset.

Active Infections

RT-PCR or Antigen tests detect the presence of SARS-CoV-2

Past Infections

Antibody tests to measure immune response to leading COVID-19 antigens

Solutions for Individuals

– Require a PCR or Antigen test for travel?

– Think you are infected with SARS-CoV-2?

– Curious if you have immunity to the virus or had a previous infection?

Randox Health have you covered!

PCR Testing

Antibody Testing

Antigen Testing

Solutions for Clinical, Pharma & Research Laboratories



Disease Management

Reagents | Extraction & qPCR

Designed to enable automated purification for accurate PCR detection of SARS-CoV-2

Viral RNA Extraction Kit

COVID-19 qPCR Assay

Surveillance | NGS Solutions for COVID-19

Identify existing & emerging SARS-CoV-2 variants

Deploying next generation sequencing aims to determine if a person has been infected with new emerging SARS-CoV-2 variants.

Available with Randox Clinical Laboratory Services (RCLS)

RCLS specialise in offering an esoteric biomarker testing service, utilising the experience and knowledge Randox has built over 40 years of producing high quality in vitro diagnostics. RCLS strive to provide a clinical laboratory testing service to meet the time sensitive, bespoke requirements of research and clinical trial projects globally.

Antibody Testing | Determine Effective Immune Response to the most Immunogenic SARS-CoV-2 Antigens

Uniquely measure antibodies reactive to both Spike Receptor Binding Domain (RBD) and Nucleocapsid protein (NP)

SARS-CoV-2 IgG (RBD & NP) Array

Simultaneous detection of neutralising SARS-CoV-2 antibodies to identify immune responses, measure vaccine efficacy and deliver an accurate estimation of herd immunity 

SARS-CoV-2 Surrogate Virus Neutralisation Assay’s

Clinical Profiling | Management & Monitoring of COVID-19 Associated Complications

Randox offers a comprehensive range of laboratory solutions including; diagnostics reagents, revolutionary Biochip technology and quality control designed to provide clinicians with valuable insights into disease severity ultimately helping to improve patient care.

Randox offer testing solutions for a comprehensive range of cytokines, cytokine receptors and growth factors designed to assist with COVID-19 risk stratification, monitoring of treatment efficacy and recovery. Utilising patented Biochip technology up to 12 cytokines and growth factors may be detected simultaneously from a single patient sample.

Cytokine storms are a common complication of SARS-CoV-2 (COVID-19) infection triggering viral sepsis, where viral replication and excessive, uncontrolled systemic inflammation may lead to pneumonitis, Acute Respiratory Distress Syndrome (ARDS), respiratory failure, shock, multiple organ failure, secondary bacterial pneumonia, and potentially death.

Cytokine Testing

In addition to tests for the detection of SARS-CoV-2, the virus that causes COVID-19, laboratory diagnostics plays a pivotal role in patient management, risk stratification, monitoring of disease progression, associated complications and response to treatment.

Patients with comorbidities such as diabetes mellitus, cardiovascular disease (CVD) and chronic kidney disease (CKD) are particularly susceptible to COVID-19 infection and are at greater risk of developing severe illness.  The Randox portfolio may also be used to diagnose and monitor such at risk patients with underlying health concerns.